Faeth Therapeutics, Inc. (FTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has a cash flow conversion efficiency ratio of -0.091x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.67 Million) by net assets ($172.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Faeth Therapeutics, Inc. (FTH) total market value for the company's overall valuation and market capitalisation.
Faeth Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Faeth Therapeutics, Inc. stock price today for real-time trading data and today's change.
Faeth Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their cash flow conversion efficiency. Review how financially flexible is Faeth Therapeutics, Inc. to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hemnet Group AB
ST:HEM
|
0.154x |
|
Yanpai Filtration Technology Co.Ltd.
SHE:301081
|
N/A |
|
Nanjing Doron Technology Corp
SHG:603528
|
0.003x |
|
Jiangsu Aoyang Technology Ltd
SHE:002172
|
0.146x |
|
Bumi Serpong Damai Tbk
JK:BSDE
|
-0.009x |
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
0.062x |
|
Shore Bancshares Inc
NASDAQ:SHBI
|
0.072x |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
0.031x |
Annual Cash Flow Conversion Efficiency for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Faeth Therapeutics, Inc. from 2018 to 2025. Also see Faeth Therapeutics, Inc. balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more